Where does Supernus Pharmaceuticals's cash flow data come from?

Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$29.02M-147%	-$38.55M-152%	-$19.12M-132%	$64.5M+1,131%	$61.91M+499%
Depreciation and amortization	$97.31M+21.6%	$91.56M+13.9%	$85.39M+2.6%	$80.69M-5.1%	$80.05M-5.8%
Stock-based compensation	$33.46M+11.8%	$33.05M+19.1%	$31.03M+16.8%	$30.88M+15.2%	$29.93M+13.6%
Deferred income taxes	$15.11M+181%	$5.21M+126%	-$13.87M+54.6%	-$17.69M+46.9%	-$18.64M+39.4%
Impairment charges	——	$0—	$0-100%	$0—	$0—
Change in accounts receivable	$13.12M+727%	$22.3M+1,173%	$2.55M—	-$11.66M—	-$2.09M—
Change in inventories	$12.34M+167%	$7.5M+147%	$135K+101%	-$17.41M+12.8%	-$18.55M-86.4%
Change in accounts payable	-$28.46M-34.9%	-$24.57M-63.6%	-$24.49M-64.8%	-$14.79M-62.1%	-$21.1M-34.2%
Change in other assets	$32.98M+535%	$13.18M-34.4%	$17.08M—	$7.69M—	$5.19M—
Other working capital changes	——	——	——	——	——
Net gains (losses) on investments	——	——	——	——	-$2.25K-200%
Non-cash operating lease expense	——	——	——	——	$5.43M-13.0%
Change in fair value of contingent consideration	$20.15M+780%	$25.42M+493%	$7.66M+215%	$6.64M+209%	$2.29M+337%
Net cash from operating activities	——	——	——	$187.06M+20.8%	$164.15M—
Capital expenditures	$1.01M+25.7%	$1.34M+84.6%	$1.12M+120%	$1.2M+159%	$804K+44.3%
Purchases of investments	$435.82M-28.9%	$475.94M-30.8%	$531.15M-17.6%	$629.45M+50.1%	$612.87M+108%
Proceeds from maturities/sales of investments	$677.5M+32.1%	$774.48M+55.2%	$868.14M+116%	$547.7M+90.1%	$512.75M+87.7%
Net cash from investing activities	——	——	——	——	-$100.93M—
Proceeds from issuance of common stock	$49.24M+251%	$37.62M+152%	$35.94M+294%	$15.66M+145%	$14.04M+93.3%
Taxes paid for net share settlement	$5.44M+15.4%	$4.23M+55.8%	$5.19M+200%	$4.76M+106%	$4.72M+63.5%
Other financing activities	$4.16M-79.3%	$24.26M—	$24.26M—	$22.4M—	$20.1M—
Net cash from financing activities	$39.64M+468%	$9.13M-25.1%	$6.49M+3.0%	-$11.5M-484%	-$10.78M+97.7%
Net increase (decrease) in cash	——	——	——	——	——
Income taxes paid	$15.37M-71.1%	$16.05M-69.9%	$28.69M-42.5%	$45.19M+22.4%	$53.19M+44.8%
Accrued product returns and rebates	$19.59M—	-$7.61M—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$32.98M+535%	$13.18M-34.4%	$17.08M—	$7.69M—	$5.19M—
Inventory write-downs	——	——	——	$8.35M+38.4%	$8.72M+29.3%
Investment Income Net Amortization Of Discount And Premium	——	——	——	——	——
Operating lease right-of-use asset amortization	——	——	——	——	$5.43M-13.0%
Other Noncash Income (Expense)	——	——	——	——	——
Payment For Contingent Consideration Liability Operating Activities	——	——	——	——	$4.9M—
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$677.5M+32.1%	$774.48M+55.2%	$868.14M+116%	$547.7M+90.1%	$512.75M—
Income Taxes Paid, Net	$15.37M-71.1%	$16.05M-69.9%	$28.69M-42.5%	$45.19M+22.4%	$53.19M+44.8%
Free cash flow	——	——	——	$185.87M+20.4%	$163.35M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Supernus Pharmaceuticals's cash flow data come from?: Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.